Norbit ASA (FRA:4NK)

Verve Therapeutics Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug 1, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	1,087	523	305	161	183	97
Market Cap Growth	88.98%	71.34%	89.36%	-11.80%	87.32%	-15.32%
Enterprise Value	1,111	560	329	189	209	106
Last Close Price	16.98	8.07	4.70	2.58	2.84	1.50
PE Ratio	40.81	25.26	18.45	15.89	38.20	37.44
PS Ratio	6.61	3.51	2.25	1.45	2.32	1.65
PB Ratio	9.95	5.31	4.31	2.83	3.68	2.34
P/TBV Ratio	38.01	11.72	5.62	3.57	4.92	2.34
P/FCF Ratio	28.35	15.72	11.42	31.29	97.85	54.96
P/OCF Ratio	25.83	14.27	9.89	19.79	38.36	11.10
EV/Sales Ratio	7.06	3.76	2.43	1.71	2.65	1.79
EV/EBITDA Ratio	26.32	16.67	11.23	10.73	21.12	18.04
EV/EBIT Ratio	30.55	19.10	12.99	13.37	28.92	25.04
EV/FCF Ratio	29.00	16.86	12.32	36.73	111.80	59.64
Debt / Equity Ratio	0.43	0.47	0.34	0.62	0.61	0.27
Debt / EBITDA Ratio	1.07	1.30	0.78	1.91	2.82	1.77
Debt / FCF Ratio	1.23	1.39	0.89	6.89	16.21	6.34
Asset Turnover	0.98	0.95	1.12	1.06	0.96	0.97
Inventory Turnover	1.33	1.41	1.24	1.59	1.70	1.76
Quick Ratio	0.97	1.12	0.53	0.57	0.69	0.78
Current Ratio	1.93	2.04	1.58	1.55	1.56	1.57
Return on Equity (ROE)	29.31%	24.95%	26.61%	19.45%	10.25%	6.20%
Return on Assets (ROA)	14.09%	11.72%	13.06%	8.47%	5.48%	4.35%
Return on Capital (ROIC)	18.88%	15.64%	17.47%	10.49%	6.67%	5.40%
Return on Capital Employed (ROCE)	24.30%	20.20%	29.40%	18.90%	10.70%	9.50%
Earnings Yield	2.45%	3.96%	5.42%	6.29%	2.62%	2.67%
FCF Yield	3.53%	6.36%	8.76%	3.20%	1.02%	1.82%
Dividend Yield	1.47%	2.11%	2.94%	2.57%	1.05%	1.91%
Payout Ratio	30.68%	38.18%	22.45%	16.40%	35.49%	124.91%
Buyback Yield / Dilution	-4.81%	-3.65%	-1.63%	-2.19%	-1.20%	-6.25%
Total Shareholder Return	-3.35%	-1.54%	1.31%	0.38%	-0.14%	-4.33%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.